Neuropharmacological Profile of Novel and Selective 5-HT6 Receptor Agonists: WAY-181187 and WAY-208466

One of the most recently identified serotonin (5-hydroxytryptamine (5-HT)) receptor subtypes is the 5-HT6 receptor. Although in-depth localization studies reveal an exclusive distribution of 5-HT6 mRNA in the central nervous system, the precise biological role of this receptor still remains unknown. In the present series of experiments, we report the pharmacological and neurochemical characterization of two novel and selective 5-HT6 receptor agonists. WAY-181187 and WAY-208466 possess high affinity binding (2.2 and 4.8 nM, respectively) at the human 5-HT6 receptor and profile as full receptor agonists (WAY-181187: EC50=6.6 nM, Emax=93%; WAY-208466: EC50=7.3 nM; Emax=100%). In the rat frontal cortex, acute administration of WAY-181187 (3–30 mg/kg, subcutaneous (s.c.)) significantly increased extracellular GABA concentrations without altering the levels of glutamate or norepinephrine. Additionally, WAY-181187 (30 mg/kg, s.c.) produced modest yet significant decreases in cortical dopamine and 5-HT levels. Subsequent studies showed that the neurochemical effects of WAY-181187 in the frontal cortex could be blocked by pretreatment with the 5-HT6 antagonist, SB-271046 (10 mg/kg, s.c.), implicating 5-HT6 receptor mechanisms in mediating these responses. Moreover, the effects of WAY-181187 on catecholamines were attenuated by an intracortical infusion of the GABAA receptor antagonist, bicuculline (10 μM), confirming a local relationship between 5-HT6 receptors and GABAergic systems in the frontal cortex. In the dorsal hippocampus, striatum, and amygdala, WAY-181187 (10–30 mg/kg, s.c.) elicited robust elevations in extracellular levels of GABA without producing similar effects on concentrations of norepinephrine, serotonin, dopamine, or glutamate. In contrast to these brain regions, WAY-181187 had no effect on the extracellular levels of GABA in the nucleus accumbens or thalamus. Additional studies showed that WAY-208466 (10 mg/kg, s.c.) preferentially elevated cortical GABA levels following both acute and chronic (14 day) administration, indicating that neurochemical tolerance does not develop following repeated 5-HT6 receptor stimulation. In hippocampal slice preparations (in vitro), 5-HT6 receptor agonism attenuated stimulated glutamate levels elicited by sodium azide and high KCl treatment. Furthermore, in the rat schedule-induced polydipsia model of obsessive compulsive disorder (OCD), acute administration of WAY-181187 (56–178 mg/kg, po) decreased adjunctive drinking behavior in a dose-dependent manner. In summary, WAY-181187 and WAY-208466 are novel, selective, and potent 5-HT6 receptor agonists displaying a unique neurochemical signature in vivo. Moreover, these data highlight a previously undescribed role for 5-HT6 receptors to modulate basal GABA and stimulated glutamate transmission, as well as reveal a potential therapeutic role for this receptor in the treatment of some types of anxiety-related disorders (eg OCD).

[1]  J. Hagan,et al.  5-HT6 receptor antagonists enhance retention of a water maze task in the rat , 2001, Psychopharmacology.

[2]  C. Marsden,et al.  5-ht6 receptors. , 2004, Current drug targets. CNS and neurological disorders.

[3]  Paul J. Harrison,et al.  The distribution of 5-HT6 receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT6 receptor antagonist [125I]SB-258585 , 2002, Brain Research.

[4]  Paul J. Harrison,et al.  The distribution of 5-HT(6) receptors in rat brain: an autoradiographic binding study using the radiolabelled 5-HT(6) receptor antagonist [(125)I]SB-258585. , 2002, Brain research.

[5]  C. Waeber,et al.  5-Hydroxytryptamine receptors with a 5-HT6 receptor-like profile stimulating adenylyl cyclase activity in pig caudate membranes , 1994, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  L. Lanfumey,et al.  Immuno-localization of serotonin 5-HT6 receptor-like material in the rat central nervous system , 1997, Brain Research.

[7]  M. Martres,et al.  Quantitative RT‐PCR distribution of serotonin 5‐HT6 receptor mRNA in the central nervous system of control or 5,7‐dihydroxytryptamine‐treated rats , 1996, Synapse.

[8]  D. Schulz,et al.  Prolonged effect of an anesthetic dose of ketamine on behavioral despair , 2002, Pharmacology Biochemistry and Behavior.

[9]  D. Sibley,et al.  Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor , 1996, Journal of neurochemistry.

[10]  L. Yatham,et al.  GABA function in mood disorders: an update and critical review. , 1998, Life sciences.

[11]  L. Lanfumey,et al.  Antibodies and Antisense Oligonucleotide for Probing the Distribution and Putative Functions of Central 5-HT6Receptors , 1999, Neuropsychopharmacology.

[12]  A. Sleight,et al.  5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.

[13]  L. Dawson,et al.  In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate , 2000, British journal of pharmacology.

[14]  A. Frugière,et al.  5-HT acting on 5-HT1/2 receptors does not participate in the in vitro hypoxic respiratory depression , 2001, Neuroscience Research.

[15]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[16]  D. Sibley,et al.  Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. , 1993, Molecular pharmacology.

[17]  S. Nawoschik,et al.  Identification of a human 5-HT6 receptor variant produced by alternative splicing. , 1999, Brain research. Molecular brain research.

[18]  D. Madison,et al.  Synaptic localization of adrenergic disinhibition in the rat hippocampus , 1991, Neuron.

[19]  V. Klimek,et al.  EFFECTS OF REPEATED TREATMENT WITH FLUOXETINE AND CITALOPRAM, A 5‐HT UPTAKE INHIBITORS ON 5‐HT1A AND 5‐HT2 RECEPTORS IN THE RAT BRAIN. , 1994, Journal of psychiatry & neuroscience : JPN.

[20]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[21]  P. Skolnick,et al.  Glutamate and depression: clinical and preclinical studies. , 2003, Annals of the New York Academy of Sciences.

[22]  L. Dawson,et al.  The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[23]  D. Dorsa,et al.  Colocalization of serotonin receptor subtypes 5‐HT2A, 5‐HT2C, and 5‐HT6 with neuropeptides in rat striatum , 1996, The Journal of comparative neurology.

[24]  P. Goldman-Rakic,et al.  Serotonergic axons in monkey prefrontal cerebral cortex synapse predominantly on interneurons as demonstrated by serial section electron microscopy , 1996, The Journal of comparative neurology.

[25]  Y. Kawaguchi,et al.  Noradrenergic Excitation and Inhibition of GABAergic Cell Types in Rat Frontal Cortex , 1998, The Journal of Neuroscience.

[26]  G. Baker,et al.  5‐Hydroxytryptamine2 and β‐Adrenergic Receptor Regulation in Rat Brain Following Chronic Treatment with Desipramine and Fluoxetine Alone and in Combination , 1994, Journal of neurochemistry.

[27]  F. Monsma,et al.  Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides. , 1995, The Journal of pharmacology and experimental therapeutics.

[28]  P. Matthews,et al.  Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. , 2004, The American journal of psychiatry.

[29]  Paul J Carlson,et al.  A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. , 2006, Archives of general psychiatry.

[30]  L. Dawson,et al.  The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus , 2001, Neuropsychopharmacology.

[31]  K. J. Murphy,et al.  The 5-HT6 Receptor Antagonist SB-271046 Reverses Scopolamine-Disrupted Consolidation of a Passive Avoidance Task and Ameliorates Spatial Task Deficits in Aged Rats , 2004, Neuropsychopharmacology.

[32]  F. Petty GABA and mood disorders: a brief review and hypothesis. , 1995, Journal of affective disorders.

[33]  J. Neumaier,et al.  5-HT6 receptors: a novel target for cognitive enhancement. , 2005, Pharmacology & therapeutics.

[34]  John H Krystal,et al.  Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. , 2004, Archives of general psychiatry.

[35]  G. Paxinos,et al.  The Rat Brain in Stereotaxic Coordinates , 1983 .

[36]  C. Beyer,et al.  Comparison of the effects of antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-vivo microdialysis study , 2002, Journal of psychopharmacology.

[37]  A. Dalvi,et al.  Acceleration of onset of action in schedule-induced polydipsia: combinations of SSRI and 5-HT1A and 5-HT1B receptor antagonists , 2004, Pharmacology Biochemistry and Behavior.

[38]  M. Breeding,et al.  Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane signaling system , 2004, Psychopharmacology.

[39]  A. Sleight,et al.  Investigation of stretching behaviour induced by the selective 5‐HT6 receptor antagonist, Ro 04–6790, in rats , 1999, British journal of pharmacology.

[40]  A. Sleight,et al.  A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze , 2001, Neuropharmacology.

[41]  H. Xue,et al.  GABAergic functions and depression: from classical therapies to herbal medicine. , 2003, Current drug targets. CNS and neurological disorders.

[42]  R. Duman,et al.  Role of neurotrophic factors in the etiology and treatment of mood disorders , 2007, NeuroMolecular Medicine.

[43]  J. Bockaert,et al.  5-HT6 receptors positively coupled to adenylyl cyclase in striatal neurones in culture. , 1994, Neuroreport.

[44]  J. Krystal,et al.  Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. , 2002, The American journal of psychiatry.

[45]  M. Cornfeldt,et al.  Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder , 2005, Psychopharmacology.

[46]  5-HT6 RECEPTORS: FUNCTIONAL CORRELATES AND POTENTIAL THERAPEUTIC INDICATIONS , 1999 .

[47]  J. Schwartz,et al.  A novel rat serotonin (5-HT6) receptor: molecular cloning, localization and stimulation of cAMP accumulation. , 1993, Biochemical and biophysical research communications.

[48]  L. Cruz-Orive,et al.  Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides , 1999, Neuroscience.

[49]  J. Krystal,et al.  Impairment of GABAergic transmission in depression: new insights from neuroimaging studies. , 2000, Critical reviews in neurobiology.

[50]  M. Bös,et al.  Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. , 2003, Journal of medicinal chemistry.

[51]  P. Skolnick,et al.  Glutamate and Depression , 2003 .

[52]  D. Sibley,et al.  Localization of serotonin subtype 6 receptor messenger RNA in the rat brain by in situ hybridization histochemistry , 1995, Neuroscience.

[53]  A. Sleight,et al.  Involvement of 5‐HT6 receptors in nigro‐striatal function in rodents , 1998, British journal of pharmacology.